This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Ahead of its all-important second-quarter fiscal 2018 earnings report, Johnson & Johnson (NYSE:JNJ) finds itself in an unenviable situation. On a year-to-date framework, JNJ is one of the worst companies in the Dow Jones Industrial Average, shedding nearly 11%. Only four other companies have worse performances. So will the JNJ earnings report turn things around or is 2018 not salvageable?
PG JNJ WBA NYTAB WMT MMM
The companies were purchased for their collective potential to deliver very solid total returns, but offering less volatility through a major market correction.
ABT LOW TXN WBA UTX CVS WMT MDT NKE JNJ CL MSFT QCOM MMM
In order to make money as a value investor, you’ve got to be willing to go against the grain and buy when the market has turned its back on a particular company. Bargain hunting on Wall Street can be a tricky business, as it is difficult to find up-and-coming stocks without the help of glowing anaylsts’ reports. However, if you’re buying after the analysts weigh in, you’ve likely already missed a huge wave of momentum.
IBM MPW WBA MS.PRE MS.PRF MS.PRG MS.PRA WMT AMZN MS.PRI MS.PRK SBUX MS
Markets closed higher on Friday, with the S&P 500 posting its highest close in more than five months. The Dow too reclaimed its 25,000 mark for the first time in almost a month. The rally was led by tech and industrial stocks, which offset a decline in financial stocks, as results from three of the major banks failed to boost investors’ confidence.
WFCNP FB MTSI C.WSA CAT WBA WFC.PRL WFC.PRJ WFC.PRT C.WS.B WFC.PRR WFC.PRQ AMZN WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS C CATR C.PRL C.PRJ C.PRK UTX C.PRG C.PRC GTT C.PRPCL CGBBW MSFT
NEW YORK: Wall Street stocks finished modestly higher on Friday (Jul 13), with the Nasdaq eking out a second straight record as beaten-down consumer stocks rallied.
WFC WFCNP WFC.WS WFC.PRL COST WBA WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
The S&P 500 posted on Friday its best closing level since early February as shares from some of the largest tech companies hit record highs.
WFC WFCNP WFC.WS WFC.PRL WBA WFC.PRJ UTX WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
July 13, 2018: Markets opened slightly higher Friday, dipped lower soon after the opening bell, and then traded mostly in the green for the rest of the day. The Nasdaq Composite traded right on the break-even line for much of the afternoon. Industrials, energy, and consumer staples were the day’s leading sectors while telecom and financials lagged. Three big banks—Citi, Wells Fargo, and JPMorgan—reported second-quarter results this morning to no boisterous reception.
WFC WFCNP WFC.WS WBA WFC.PRL WFC.PRJ UTX WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN BOE WFC.PRY BA WFC.PRX WFC.PRW DIS WFC.PRV
Shares of Walgreens Boots Alliance (WBA - Free Report) are down 16.5% over the last year based mostly on Amazon (AMZN - Free Report) fears. There is no doubt that online selling and delivery have altered the retail world, but does that mean Walgreens can no longer compete? Let’s dive into some of WBA’s fundamentals to see what to do with the stock.
TGT RAD WBA WMT
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
21h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
23h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to WBA / Walgreens Boots Alliance, Inc. on message board site Silicon Investor.
|Walgreen Boots Alliance - WBA||Snowball.com, Inc. (Nasdaq - SNOW)|
as of ET